Erik Harris is the Chief Commercial Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare genetic diseases. In his role at Ultragenyx, Harris is responsible for overseeing the company's global commercial strategy, which includes the launch and expansion of their product portfolio. His leadership has been instrumental in driving the company's growth and establishing its presence in the competitive rare disease market. Prior to joining Ultragenyx, Harris held several key positions in the pharmaceutical industry, showcasing his extensive experience in commercial operations and strategic planning. He spent over a decade at Genentech, where he served as Vice President of Sales and Marketing for their BioOncology business unit. During his tenure, he played a pivotal role in the successful launch and commercialization of multiple oncology products, significantly contributing to the company's revenue growth. Before Genentech, Harris worked at Amgen, where he held various commercial leadership roles, further honing his skills in product launches and market expansion. Harris's achievements in the pharmaceutical industry are marked by his ability to navigate complex markets and deliver results. At Ultragenyx, he has been crucial in the successful launch of Crysvita, a treatment for X-linked hypophosphatemia (XLH), and Dojolvi, a treatment for long-chain fatty acid oxidation disorders (LC-FAOD). His strategic vision and execution have not only helped in bringing these life-changing therapies to patients but have also positioned Ultragenyx as a leader in the rare disease space. Harris's dedication to improving patient outcomes and his expertise in commercial strategy continue to drive the company's mission forward.